Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) ...

A lower initial lung diffusion capacity for carbon monoxide is associated with a higher rate of progression from very early diagnosis to definite systemic sclerosis.

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.

SAQE, a tool with over 90% accuracy for diagnosing Hypersensitivity Pneumonitis. This lung condition, prevalent in South Asia, leads to fibrosis. The tool uses a questionnaire to assess environmental ...

A subgroup of patients with SSc who exhibit a severe GI phenotype were associated with longer disease duration, ACA positivity, PAH, and worse quality of life.